Rucaparib or Physician's Choice in Metastatic Prostate Cancer
Por um escritor misterioso
Descrição
PDF) The TRITON programme: evaluation of the PARP inhibitor rucaparib in patients with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination deficiency (HRD)
Rucaparib Bests Physician's Choice for BRCA+ mCRPC
Rucaparib or Physician's Choice in Metastatic Prostate Cancer
Optimizing Therapeutic Strategies in Castration-Resistant Prostate Cancer
Clovis trots out Rubraca prostate cancer partial win
Rucaparib improves rPFS vs docetaxel or 2nd-generation ARPI in BRCA-mutated mCRPC, Latest news for Doctors, Nurses and Pharmacists
Rucaparib Bests Physician's Choice in Metastatic Castration-Resistant Prostate Cancer - Cancer Therapy Advisor
Prostate cancer and PARP inhibitors: progress and challenges, Journal of Hematology & Oncology
PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer: Whom to Treat?
Rucaparib or physician's choice in metastatic prostate cancer -ORCA
de
por adulto (o preço varia de acordo com o tamanho do grupo)
